Galectin-3 Expression in Normal, Hyperplastic, and Neoplastic Endometrial Tissues

Brustmann, Hermann; Riss, Dominik; Naudé, S. M.

doi:10.1078/0344-0338-00368

Cited by 29 publications

(26 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, galectin-1 was found to be increased in endometrioid EMCAR from well differentiated to undifferentiated carcinoma [59]. Contradictory to the data by Van den Brule et al [58], Brustmann et al [60] were able to show an increase in galectin-3 in EMCAR samples compared with normal endometrium samples. However, Ege et al [61] reported decreased galectin-3 expression in EMCAR samples compared with normal endometrium.…”

Section: Discussionmentioning

confidence: 84%

“…In cancer, there is often a change in intracellular localization of galectin-3. Brustmann et al [60] found an increased nuclear expression in EMCAR. Data of Mylonas et al showed that it can be detected in both the cytoplasm and the nucleus [58], but exclusively, cytoplasmic expression was associated with increased myometrial invasion of EMCAR [58].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy

Vanderstraeten

Luyten

Verbist

et al. 2014

Cancer Immunol Immunother

109

101

View full text Add to dashboard Cite

The major hurdle for cancer vaccines to be effective is posed by tumor immune evasion. Several common immune mechanisms and mediators are exploited by tumors to avoid immune destruction. In an attempt to shed more light on the immunosuppressive environment in uterine tumors, we analyzed the presence of PD-L1, PD-L2, B7-H4, indoleamine 2,3-dioxygenase (IDO), galectin-1, galectin-3, arginase-1 activity and myeloid-derived suppressor cell (MDSC) infiltration. IDO, PD-L1, PD-L2 and B7-H4 were analyzed by immunohistochemistry. PD-L2 was mostly expressed at low levels in these tumors. We found high IDO expression in 21 % of endometrial carcinoma samples and in 14 % of uterine sarcoma samples. For PD-L1 and B7-H4, we found high expression in 92 and 90 % of endometrial cancers, respectively, and in 100 and 92 % of the sarcomas. Galectin-1 and 3 were analyzed in tissue lysates by ELISA, but we did not find an increase in both molecules in tumor lysates compared with benign tissues. We detected expression of galectin-3 by fibroblasts, immune cells and tumor cells in single-cell tumor suspensions. In addition, we noted a highly significant increase in arginase-1 activity in endometrial carcinomas compared with normal endometria, which was not the case for uterine sarcomas. Finally, we could demonstrate MDSC infiltration in fresh tumor suspensions from uterine tumors. These results indicate that the PD-1/PD-L1 interaction and B7-H4 could be possible targets for immune intervention in uterine cancer patients as well as mediation of MDSC function. These observations are another step toward the implementation of inhibitors of immunosuppression in the treatment of uterine cancer patients.Electronic supplementary materialThe online version of this article (doi:10.1007/s00262-014-1537-8) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy

Vanderstraeten

Luyten

Verbist

et al. 2014

Cancer Immunol Immunother

109

101

View full text Add to dashboard Cite

show abstract

“…van den Brûle et al (37) reported that the expression levels of galectin-1, but not galectin-3, were upregulated in endometrial carcinoma, as compared with normal endometrium. Similarly, galectin-1 expression levels have been demonstrated to be upregulated in undifferentiated cancer, as compared with differentiated cancer (38). Conversely, Brustmann et al (38) reported that the expression levels of galectin-3 were upregulated in endometrial carcinoma, as compared with normal endometrium, whereas Ege et al (39) reported that the expression levels of galectin-3 were decreased in endometrial carcinoma, as compared with normal endometrium.…”

Section: B Amentioning

confidence: 92%

“…Similarly, galectin-1 expression levels have been demonstrated to be upregulated in undifferentiated cancer, as compared with differentiated cancer (38). Conversely, Brustmann et al (38) reported that the expression levels of galectin-3 were upregulated in endometrial carcinoma, as compared with normal endometrium, whereas Ege et al (39) reported that the expression levels of galectin-3 were decreased in endometrial carcinoma, as compared with normal endometrium. The results of the present study suggested that the expression levels of galectin-1 and galectin-3 were not significantly different between normal and tumor tissues.…”

Section: B Amentioning

confidence: 92%

“…The localization of galectin-3 has been reported to alter between various cancers (39). Brustmann et al (38) demonstrated increased expression of galectin-3 in the nucleus of endometrial carcinoma specimens, whereas Mylonas et al (40) reported galectin-3 expression in the cytoplasm and nucleus. However, the expression of galectin-3 in the cytoplasm has previously been associated with the invasion of the muscle layer near endometrial carcinoma (37), although this correlation was not demonstrated in the present study.…”

Section: B Amentioning

confidence: 98%

See 1 more Smart Citation

Expression of immune checkpoint molecules in endometrial carcinoma

Liu

Wang

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The main obstacle in the development of an effective tumor vaccine is the inherent ability of tumors to evade immune responses. Tumors often use common immune mechanisms and regulators to evade the immune system. The present study aimed to analyze the expression levels of indoleamine 2,3-dioxygenase (IDO), programmed death-ligand (PD-L) 1, PD-L2, B7-H4, galectin-1 and galectin-3 in tissue samples from patients with endometrial carcinoma, in order to detect the immunosuppressive environment of endometrial carcinomas. The levels of IDO, PD-L1, PD-L2 and B7-H4 were analyzed by immunohistochemical methods, and the levels of galectin-1 and galectin-3 in tumor lysates were determined using ELISA. PD-L2 was expressed at low levels in the majority of tumor samples. IDO expression was detected in 38, 63 and 43% of primary endometrial carcinoma, recurrent endometrial carcinoma, and metastatic endometrial carcinoma specimens, respectively. Positive expression rates for PD-L1 were 83% in primary endometrial carcinoma, 68% in recurrent endometrial carcinoma, and 100% in metastatic endometrial carcinoma, whereas B7-H4 expression was detected in 100% of both primary endometrial carcinoma and recurrent endometrial carcinoma samples, and in 96% of metastatic endometrial carcinoma specimens. The expression levels of galectin-1 and galectin-3 were not significantly different between the normal and tumor specimens. The results of the present study suggest that the interaction between PD-1/PD-L1 and B7-H4 may be a potential target for immune intervention in the treatment of endometrial carcinoma. Furthermore, the results may provide the basis for immunosuppressant therapy in the treatment of patients with uterine cancer.

show abstract

SEREX identification of new tumor antigens linked to melanoma-associated retinopathy

et al. 2005

View full text Add to dashboard Cite

Metastatic melanoma still has a very poor prognosis since it withstands conventional therapies like surgery or chemotherapy. A paraneoplastic autoimmune manifestation of this disease is melanoma-associated retinopathy (MAR). MAR has been associated with prolonged survival and may be an early marker of tumor progression. By screening a retina and a melanoma cDNA phage library by SEREX using sera of patients suffering from melanoma and, in some cases, clinical symptoms of MAR, we identified 20 new antigens (HD-MM-28 -47), of which 14 clones had high homology to well-known genes. Six of these genes had previously been associated with retina: rhodopsin, visual arrestin, MEK1, SRPX, BBS1 and galectin-3.

show abstract

Galectin-3 Expression in Normal, Hyperplastic, and Neoplastic Endometrial Tissues

Cited by 29 publications

References 28 publications

Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy

Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy

Expression of immune checkpoint molecules in endometrial carcinoma

SEREX identification of new tumor antigens linked to melanoma-associated retinopathy

Contact Info

Product

Resources

About